Sangamo exits ST-920 gene therapy assets in Chapter 11 sale to PTC for USD 111 million

By Public Technologies
  • Sangamo Therapeutics completed the sale of ST-920 Fabry gene-therapy assets to PTC Therapeutics on Sept. 17, 2026.
  • Consideration totaled USD 111 million in cash at closing.
  • Deal includes up to USD 100 million of milestone-based contingent payments.
  • PTC also assumed certain specified liabilities tied to the transferred assets.
  • Common stock remains suspended from Nasdaq trading, now quoted on OTCID Basic Market under symbol SGMOQ.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-396644), on September 21, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.